All In Biotech

Drug Trial Radar · NCT02721433

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study

Last checked: Nov 20, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

263

Actual

Start

Aug 2016

Primary completion

Sep 2019

Study completion Apr 2020

Sponsor

Lead sponsor
Ottawa Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System. This study will use an "integrated consent model" that involves "oral consent" rather than a written informed consent writing process as the study is comparing standard schedules and not a new administration schedule.

Conditions

  • Breast Cancer
  • Prostate Cancer
  • Metastasis

Interventions

  • PamidronateDrug

    Bone-targeted agent as standard of care

  • DenosumabDrug

    Bone-targeted agent as standard of care

  • ZoledronateDrug

    Bone-targeted agent as standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health related quality of life scores measured with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Functional Domain (Physical Subdomain)Time frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.